KETOCONAZOLE
本记录确认了用于欧盟化妆品标签标示的官方通用成分名称。它本身并不能确认该物质获准使用、不受限制或安全。
全球证据概览
所解析的身份在 13 个已索引市场数据集中的 8 个有匹配的监管证据:8 条国家记录和 0 条欧盟附件记录。下方列出每项结果和证据缺口。
已解析的物质身份
Ketoconazole is the heterocyclic compound that conforms to the formula
清单限制备注: II/1528
8 个匹配或报告的名称
全部 13 个市场的监管证据
打开每条匹配记录,查看其范围、浓度、条件、警示语和官方来源版本。
滑动或横向滚动以查看数据集覆盖范围和后续操作。
| 市场 | 结果 | 记录 | 数据集 | 含义 / 后续操作 |
|---|---|---|---|---|
| European Union EU | 未找到匹配项 | 0 | Complete annex dataset Regulation (EC) 1223/2009 consolidated to 1 May 2026 | No annex match only means that these five annexes did not return a match; CosIng identity data and other EU obligations still need review. |
| Great Britain GB | Prohibited | 1打开记录 1 | Complete consolidated annex dataset GB retained Regulation 1223/2009 schedules, effective 15 August 2026 | 请查看每条关联记录及其确切条件。 |
| Canada CA | 未找到匹配项 | 0 | Complete Hotlist snapshot Health Canada Cosmetic Ingredient Hotlist, 13 August 2025 | The Hotlist is an administrative compliance tool, not an exhaustive safety approval list. |
| New Zealand NZ | Prohibited | 1打开记录 1 | Complete schedules dataset Cosmetic Products Group Standard schedules effective 1 January 2026 | 请查看每条关联记录及其确切条件。 |
| ASEAN ASEAN | Prohibited | 1打开记录 1 | Complete regional annex dataset ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026 | 请查看每条关联记录及其确切条件。 |
| China CN | Prohibited | 1打开记录 1 | Complete prohibited catalogues plus official-source workflow NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025 | 请查看每条关联记录及其确切条件。 |
| Japan JP | 未找到匹配项 | 0 | Complete Standards appendices dataset MHLW Standards for Cosmetics official English source and Japanese amendments checked for the imported snapshot | The Japanese text and subsequent notices are canonical; no local match is not a product-compliance conclusion. |
| South Korea KR | Prohibited | 1打开记录 1 | Complete current appendix dataset MFDS Notice 2026-19, effective 18 March 2026 | 请查看每条关联记录及其确切条件。 |
| United States US | 未找到匹配项 | 0 | Complete enumerated federal ingredient rules eCFR Title 21 issue date 27 August 2026 | FDA has no general approved-cosmetic-ingredient catalogue; absence from these sections is not approval or proof of safety. |
| Australia AU | 未找到匹配项 | 0 | Complete cosmetic-relevant Poisons Standard subset plus official workflow Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026 | An AICIS Inventory match is not cosmetic approval; no Inventory match can indicate a new, exempted, reported or confidential introduction. |
| Brazil BR | Prohibited | 1打开记录 1 | Complete prohibited dataset plus current restricted-list workflow ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026 | 请查看每条关联记录及其确切条件。 |
| India IN | Prohibited | 1打开记录 1 | Complete current Part 2 dataset plus official workflow for Parts 1, 3 and 4 Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022) | 请查看每条关联记录及其确切条件。 |
| Saudi Arabia SA | Prohibited | 1打开记录 1 | Complete official list index SFDA live prohibited/restricted lists, snapshot 30 August 2026 | 请查看每条关联记录及其确切条件。 |
匹配的市场记录和条件
New Zealand
Cosmetic Products Group Standard schedules effective 1 January 2026ASEAN
ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026South Korea
MFDS Notice 2026-19, effective 18 March 2026Brazil
ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026India
Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022)Saudi Arabia
SFDA live prohibited/restricted lists, snapshot 30 August 2026化学身份与性质

Tyrothricin
Tyrothricin is an antibiotic peptide complex produced and extracted from the aerobic Gram-positive bacillus Brevibacillus parabrevis which was previously categorized as Bacillus brevis and Bacillus aneurinolyticus. This complex is a mixture comprised of 60% tyrocidine cationic cyclic decapeptides (consisting largely of the six predominant tyrocidines, TrcA/A1, TrcB/B1, TrcC/C1, and other more minor contributors) and 40% neutral linear gramicidins (where valine-gramicidin A is often the major gramicidin present, although the mixture composition can vary). Moreover, tyrothricin possesses broad spectrum Gram-positive antibacterial and antifungal activity that has not seen many - if any - significant reportings of microbial resistance during the over 60 years of therapeutic use the complex has provided. Nevertheless, as tyrothricin is both cytolytic and hemolytic, it does demonstrate systemic toxicity, although certain formulations that are safe for human use like throat lozenges do exist. — DrugBank
- IUPAC 名称
- 3-[(3R,6S,9S,12S,15S,17S,20S,22R,25S,28S)-20-(2-amino-2-oxoethyl)-9-(3-aminopropyl)-3,22,25-tribenzyl-15-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,14,18,21,24,27-nonaoxo-12-propan-2-yl-1,4,7,10,13,16,19,23,26-nonazabicyclo[26.3.0]hentriacontan-17-yl]propanoic acid
- 分子式
- C65H85N11O13
- 分子量
- 1228.4 g/mol
- 精确质量
- 1227.63283181 Da
- XLogP3
- 1.9
- 拓扑极性表面积
- 380.0 Ų
- 氢键供体
- 12
- 氢键受体
- 15
- 共价单元
- 1
- 已定义的立体中心
- 10
又称
另有 16 个已报告名称
外部数据库标识符
- ChEMBL:CHEMBL577736
于 2026-09-02 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

Metronidazole
Metronidazole is a member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death. It has a role as a radiosensitizing agent, an antiamoebic agent, an antimicrobial agent, an antiparasitic agent, a xenobiotic, an antibacterial drug, a prodrug, an antitrichomonal drug and an environmental contaminant. It is a primary alcohol, a member of imidazoles and a C-nitro compound. It is a conjugate base of a metronidazole(1+). — ChEBI
- IUPAC 名称
- 2-(2-methyl-5-nitroimidazol-1-yl)ethanol
- 分子式
- C6H9N3O3
- 分子量
- 171.15 g/mol
- 精确质量
- 171.06439116 Da
- XLogP3
- 0.0
- 拓扑极性表面积
- 83.9 Ų
- 氢键供体
- 1
- 氢键受体
- 4
- 共价单元
- 1
- 已定义的立体中心
- 0
又称
另有 16 个已报告名称
外部数据库标识符
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

Ethionamide
Ethionamide is a thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide. It has a role as an antitubercular agent, an antilipemic drug, a leprostatic drug, a fatty acid synthesis inhibitor and a prodrug. It is a member of pyridines and a thiocarboxamide. — ChEBI
- IUPAC 名称
- 2-ethylpyridine-4-carbothioamide
- 分子式
- C8H10N2S
- 分子量
- 166.25 g/mol
- 精确质量
- 166.05646950 Da
- XLogP3
- 1.1
- 拓扑极性表面积
- 71.0 Ų
- 氢键供体
- 1
- 氢键受体
- 2
- 共价单元
- 1
- 已定义的立体中心
- 0
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:4885
- ChEMBL:CHEMBL1441
- EPA DTXSID:DTXSID0020577
- PubMed:33814510
- PubMed:32808185
- PubMed:26708503
- PubMed:26062974
- PubMed:25051504
- PubMed:23112434
- PubMed:23107633
- PubMed:23106273
- PubMed:23020577
- PubMed:23019444
- PubMed:22952439
- PubMed:22904807
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

Methimazole
Methimazole is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen. It has a role as an antithyroid drug. — ChEBI
- IUPAC 名称
- 3-methyl-1H-imidazole-2-thione
- 分子式
- C4H6N2S
- 分子量
- 114.17 g/mol
- 精确质量
- 114.02516937 Da
- XLogP3
- -0.3
- 拓扑极性表面积
- 47.4 Ų
- 氢键供体
- 1
- 氢键受体
- 1
- 共价单元
- 1
- 已定义的立体中心
- 0
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:50673
- ChEMBL:CHEMBL1515
- EPA DTXSID:DTXSID4020820
- PubMed:41580965
- PubMed:38685447
- PubMed:34788025
- PubMed:34757178
- PubMed:33814510
- PubMed:32808185
- PubMed:32020584
- PubMed:31697382
- PubMed:31629072
- PubMed:31066087
- PubMed:30814441
- PubMed:30320502
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

Ketoconazole
(2S,4R)-ketoconazole is a cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine which dioxolane moiety has (2S,4R)-configuration. It is an enantiomer of a (2R,4S)-ketoconazole. — ChEBI
- IUPAC 名称
- 1-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone
- 分子式
- C26H28Cl2N4O4
- 分子量
- 531.4 g/mol
- 精确质量
- 530.1487608 Da
- XLogP3
- 4.3
- 拓扑极性表面积
- 69.1 Ų
- 氢键供体
- 0
- 氢键受体
- 6
- 共价单元
- 1
- 已定义的立体中心
- 2
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:47518
- ChEMBL:CHEMBL295698
- EPA DTXSID:DTXSID60161949
- PubMed:40976440
- PubMed:38795739
- PubMed:38734219
- PubMed:37788138
- PubMed:37077353
- PubMed:36893891
- PubMed:36653537
- PubMed:36621641
- PubMed:36374910
- PubMed:36332690
- PubMed:35478211
- PubMed:35358606
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

Nitrofurantoin
Nitrofurantoin is an imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA. It has a role as an antiinfective agent, an antibacterial drug and a hepatotoxic agent. It is an imidazolidine-2,4-dione, an organonitrogen heterocyclic antibiotic, an organooxygen heterocyclic antibiotic and a nitrofuran antibiotic. It is functionally related to a semicarbazide. — ChEBI
- IUPAC 名称
- 1-[(E)-(5-nitrofuran-2-yl)methylideneamino]imidazolidine-2,4-dione
- 分子式
- C8H6N4O5
- 分子量
- 238.16 g/mol
- 精确质量
- 238.03381930 Da
- XLogP3
- -0.5
- 拓扑极性表面积
- 121.0 Ų
- 氢键供体
- 1
- 氢键受体
- 6
- 共价单元
- 1
- 已定义的立体中心
- 0
又称
另有 16 个已报告名称
外部数据库标识符
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

Furazolidone
Furazolidone is a member of the class of oxazolidines that is 1,3-oxazolidin-2-one in which the hydrogen attached to the nitrogen is replaced by an N-{[(5-nitro-2-furyl)methylene]amino} group. It has antibacterial and antiprotozoal properties, and is used in the treatment of giardiasis and cholera. It has a role as an antiinfective agent, an antibacterial drug, an EC 1.4.3.4 (monoamine oxidase) inhibitor and an antitrichomonal drug. It is a member of oxazolidines and a nitrofuran antibiotic. — ChEBI
- IUPAC 名称
- 3-[(E)-(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one
- 分子式
- C8H7N3O5
- 分子量
- 225.16 g/mol
- 精确质量
- 225.03857033 Da
- XLogP3
- -0.1
- 拓扑极性表面积
- 101.0 Ų
- 氢键供体
- 0
- 氢键受体
- 6
- 共价单元
- 1
- 已定义的立体中心
- 0
又称
另有 16 个已报告名称
外部数据库标识符
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

Dihydrotachysterol
Dihydrotachysterol is a hydroxy seco-steroid that is 9,10-secoergosta-5,7,22-triene substituted by a hydroxy group at position 3. A synthetic analogue of vitamin D that acts a bone density conservation agent. It has a role as a bone density conservation agent. It is a vitamin D, a seco-ergostane and a hydroxy seco-steroid. — ChEBI
- IUPAC 名称
- trans-(1S,3E,4S)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylcyclohexan-1-ol
- 分子式
- C28H46O
- 分子量
- 398.7 g/mol
- 精确质量
- 398.354866087 Da
- XLogP3
- 7.7
- 拓扑极性表面积
- 20.2 Ų
- 氢键供体
- 1
- 氢键受体
- 1
- 共价单元
- 1
- 已定义的立体中心
- 7
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:4591
- ChEMBL:CHEMBL2356023
- EPA DTXSID:DTXSID5022938
- PubMed:15585789
- PubMed:10515239
- PubMed:6262039
- PubMed:4365509
- PubMed:3320562
- PubMed:198519
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。

3,4',5-Tribromosalicylanilide
Tribromosalicylanilide is a salicylanilide derivative with bromo- substituents at C-3 and C-5 of the salicylate moiety and at C-4 of the anilide moiety. It is functionally related to a salicylanilide. — ChEBI
- IUPAC 名称
- 3,5-dibromo-N-(4-bromophenyl)-2-hydroxybenzamide
- 分子式
- C13H8Br3NO2
- 分子量
- 449.92 g/mol
- 精确质量
- 448.80847 Da
- XLogP3
- 5.0
- 拓扑极性表面积
- 49.3 Ų
- 氢键供体
- 2
- 氢键受体
- 2
- 共价单元
- 1
- 已定义的立体中心
- 0
又称
另有 16 个已报告名称
外部数据库标识符
- ChEBI:CHEBI:127105
- ChEMBL:CHEMBL24944
- EPA DTXSID:DTXSID4026181
- PubMed:33352258
- PubMed:21826158
- PubMed:20922970
- PubMed:20067776
- PubMed:19668425
- PubMed:18479921
- PubMed:17228788
- PubMed:12755728
于 2026-09-02 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。
官方来源与范围
导入自委员会实施决定 (EU) 2025/1175(数据集版本 EU 2025/1175)。词汇表为第 19(1)(g) 条所要求的成分表提供通用成分名称;它不是准许清单或安全清单。
打开官方决定